JP2015091877A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015091877A5 JP2015091877A5 JP2015021023A JP2015021023A JP2015091877A5 JP 2015091877 A5 JP2015091877 A5 JP 2015091877A5 JP 2015021023 A JP2015021023 A JP 2015021023A JP 2015021023 A JP2015021023 A JP 2015021023A JP 2015091877 A5 JP2015091877 A5 JP 2015091877A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- amount
- present
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims 27
- 239000008194 pharmaceutical composition Substances 0.000 claims 25
- 239000000203 mixture Substances 0.000 claims 11
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 claims 10
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims 10
- 239000008213 purified water Substances 0.000 claims 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 8
- 239000002904 solvent Substances 0.000 claims 8
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 claims 6
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims 5
- 235000017557 sodium bicarbonate Nutrition 0.000 claims 5
- 239000006068 taste-masking agent Substances 0.000 claims 5
- 235000011187 glycerol Nutrition 0.000 claims 4
- 239000007788 liquid Substances 0.000 claims 4
- 159000000000 sodium salts Chemical class 0.000 claims 4
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 claims 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims 3
- 229960004998 acesulfame potassium Drugs 0.000 claims 3
- 235000010358 acesulfame potassium Nutrition 0.000 claims 3
- 239000000619 acesulfame-K Substances 0.000 claims 3
- 239000003755 preservative agent Substances 0.000 claims 3
- 230000002335 preservative effect Effects 0.000 claims 3
- 239000000600 sorbitol Substances 0.000 claims 3
- 239000004094 surface-active agent Substances 0.000 claims 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 claims 2
- 239000011877 solvent mixture Substances 0.000 claims 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical group [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 229930006000 Sucrose Natural products 0.000 claims 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 1
- 239000003205 fragrance Substances 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 239000000845 maltitol Substances 0.000 claims 1
- 235000010449 maltitol Nutrition 0.000 claims 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 claims 1
- 229940035436 maltitol Drugs 0.000 claims 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 claims 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 claims 1
- 229960002216 methylparaben Drugs 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 claims 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 claims 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 claims 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 claims 1
- 229960003415 propylparaben Drugs 0.000 claims 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims 1
- 229960002920 sorbitol Drugs 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 239000005720 sucrose Substances 0.000 claims 1
- 229960004793 sucrose Drugs 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23021209P | 2009-07-31 | 2009-07-31 | |
| US61/230,212 | 2009-07-31 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012522810A Division JP2013500965A (ja) | 2009-07-31 | 2010-07-28 | 癌および他の疾患または障害の治療のための医薬組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015091877A JP2015091877A (ja) | 2015-05-14 |
| JP2015091877A5 true JP2015091877A5 (enExample) | 2015-12-17 |
| JP6014695B2 JP6014695B2 (ja) | 2016-10-25 |
Family
ID=42697590
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012522810A Pending JP2013500965A (ja) | 2009-07-31 | 2010-07-28 | 癌および他の疾患または障害の治療のための医薬組成物 |
| JP2015021023A Active JP6014695B2 (ja) | 2009-07-31 | 2015-02-05 | 癌および他の疾患または障害の治療のための医薬組成物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012522810A Pending JP2013500965A (ja) | 2009-07-31 | 2010-07-28 | 癌および他の疾患または障害の治療のための医薬組成物 |
Country Status (30)
| Country | Link |
|---|---|
| US (3) | US20110039826A1 (enExample) |
| EP (1) | EP2459173B1 (enExample) |
| JP (2) | JP2013500965A (enExample) |
| KR (1) | KR101762285B1 (enExample) |
| CN (2) | CN102548539A (enExample) |
| AR (1) | AR077436A1 (enExample) |
| AU (1) | AU2010276741B2 (enExample) |
| BR (1) | BR112012002265B8 (enExample) |
| CA (1) | CA2769531C (enExample) |
| CL (1) | CL2012000261A1 (enExample) |
| CO (1) | CO6612185A2 (enExample) |
| CR (1) | CR20120084A (enExample) |
| EA (1) | EA025277B1 (enExample) |
| EC (1) | ECSP12011703A (enExample) |
| GE (1) | GEP201606513B (enExample) |
| IL (1) | IL217839A (enExample) |
| IN (1) | IN2012DN01237A (enExample) |
| JO (1) | JO3434B1 (enExample) |
| MA (1) | MA33533B1 (enExample) |
| MX (2) | MX2012001196A (enExample) |
| MY (1) | MY174084A (enExample) |
| NZ (1) | NZ598096A (enExample) |
| PE (1) | PE20120788A1 (enExample) |
| SG (2) | SG10201404483VA (enExample) |
| TN (1) | TN2012000046A1 (enExample) |
| TW (1) | TWI522357B (enExample) |
| UA (1) | UA110463C2 (enExample) |
| UY (1) | UY32822A (enExample) |
| WO (1) | WO2011014248A1 (enExample) |
| ZA (1) | ZA201200944B (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101792651B1 (ko) * | 2004-05-14 | 2017-11-20 | 밀레니엄 파머슈티컬스 인코퍼레이티드 | 아우로라 키나아제의 억제에 의해 유사분열 진행을 억제하기 위한 화합물 및 그 화합물을 포함하는 약학적 조성물 |
| CN102264368B (zh) | 2008-12-22 | 2014-09-10 | 米伦纽姆医药公司 | 极光激酶抑制剂与抗cd20抗体的组合 |
| JO3635B1 (ar) | 2009-05-18 | 2020-08-27 | Millennium Pharm Inc | مركبات صيدلانية صلبة وطرق لانتاجها |
| JO3434B1 (ar) | 2009-07-31 | 2019-10-20 | Millennium Pharm Inc | مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري |
| TWI392514B (zh) * | 2010-01-29 | 2013-04-11 | Colgate Palmolive Co | 具有高微生物效力之不含氟化物及陰離子表面活性劑的潔牙劑 |
| WO2011103089A1 (en) | 2010-02-19 | 2011-08-25 | Millennium Pharmaceuticals, Inc. | Crystalline forms of sodium 4-{[9-chloro-7-(2-fluoro-6--methoxyphenyl)-5h -pyrimido[5,4-d][2]benzazepin-2yl]amino}-2-methoxybenzoate |
| AR086656A1 (es) | 2011-06-03 | 2014-01-15 | Millennium Pharm Inc | Combinacion de inhibidores de mek e inhibidores selectivos de la quinasa aurora a |
| US20130303519A1 (en) | 2012-03-20 | 2013-11-14 | Millennium Pharmaceuticals, Inc. | Methods of treating cancer using aurora kinase inhibitors |
| EP2976086B1 (en) | 2013-03-22 | 2020-10-14 | Millennium Pharmaceuticals, Inc. | Combination of catalytic mtorc 1/2 inhibitors and selective inhibitors of aurora a kinase |
| US10335494B2 (en) | 2013-12-06 | 2019-07-02 | Millennium Pharmaceuticals, Inc. | Combination of aurora kinase inhibitors and anti-CD30 antibodies |
| EP3324976A4 (en) | 2015-07-21 | 2019-03-27 | Millennium Pharmaceuticals, Inc. | ADMINISTRATION OF KINASE AURORA INHIBITOR AND CHEMOTHERAPEUTIC AGENTS |
| USD797120S1 (en) | 2015-08-28 | 2017-09-12 | Samsung Electronics Co., Ltd. | Display screen or portion thereof with graphical user interface |
| IL327467A (en) | 2023-10-03 | 2026-05-01 | Takeda Pharmaceutical Co Limited | Elisartib and paclitaxel for the treatment of small cell lung cancer |
| WO2025245045A1 (en) | 2024-05-21 | 2025-11-27 | The Regents Of The University Of California | Methods of treating lung cancer |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5747487A (en) * | 1993-07-29 | 1998-05-05 | American Cyanamid Company | Tricyclic benzazepine vasopressin antagonists |
| AU5330698A (en) | 1996-12-23 | 1998-07-17 | Celltech Therapeutics Limited | Fused polycyclic 2-aminopyrimidine derivatives, their preparation and their use as protein tyrosine kinase inhibitors |
| WO2001010462A1 (en) | 1999-08-11 | 2001-02-15 | Idec Pharmaceuticals Corporation | Treatment of patients having non-hodgkins lymphoma with bone marrow involvement with anti-cd20 antibodies |
| KR20030019328A (ko) * | 2000-03-24 | 2003-03-06 | 아이박스 리서치 인코포레이티드 | 탁산-기저 조성물 및 이를 이용한 방법 |
| US6982253B2 (en) * | 2002-06-05 | 2006-01-03 | Supergen, Inc. | Liquid formulation of decitabine and use of the same |
| KR101792651B1 (ko) * | 2004-05-14 | 2017-11-20 | 밀레니엄 파머슈티컬스 인코퍼레이티드 | 아우로라 키나아제의 억제에 의해 유사분열 진행을 억제하기 위한 화합물 및 그 화합물을 포함하는 약학적 조성물 |
| US20070104785A1 (en) * | 2005-07-29 | 2007-05-10 | Navale Suryakant V | Tablets of linezolid form iii and processes for their preparation |
| WO2007076348A2 (en) * | 2005-12-23 | 2007-07-05 | Smithkline Beecham Corporation | Azaindole inhibitors of aurora kinases |
| CA2656393A1 (en) | 2006-06-30 | 2008-01-10 | Schering Corporation | Method of using substituted piperidines that increase p53 activity |
| BRPI0715423A2 (pt) * | 2006-07-21 | 2013-07-02 | Novartis Ag | formulaÇÕes para Éteres de benzimidazolil piridila |
| WO2008021038A2 (en) | 2006-08-09 | 2008-02-21 | Millennium Pharmaceuticals, Inc. | Pyridobenzazepine compounds and methods for inhibiting mitotic progression |
| CL2007003244A1 (es) * | 2006-11-16 | 2008-04-04 | Millennium Pharm Inc | Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer. |
| US20090203671A1 (en) * | 2007-11-27 | 2009-08-13 | Abbott Laboratories | Method of treating cancer |
| CN102264368B (zh) * | 2008-12-22 | 2014-09-10 | 米伦纽姆医药公司 | 极光激酶抑制剂与抗cd20抗体的组合 |
| JO3635B1 (ar) * | 2009-05-18 | 2020-08-27 | Millennium Pharm Inc | مركبات صيدلانية صلبة وطرق لانتاجها |
| JO3434B1 (ar) | 2009-07-31 | 2019-10-20 | Millennium Pharm Inc | مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري |
| WO2011103089A1 (en) * | 2010-02-19 | 2011-08-25 | Millennium Pharmaceuticals, Inc. | Crystalline forms of sodium 4-{[9-chloro-7-(2-fluoro-6--methoxyphenyl)-5h -pyrimido[5,4-d][2]benzazepin-2yl]amino}-2-methoxybenzoate |
-
2010
- 2010-07-26 JO JOP/2010/0264A patent/JO3434B1/ar active
- 2010-07-28 BR BR112012002265A patent/BR112012002265B8/pt active IP Right Grant
- 2010-07-28 MX MX2012001196A patent/MX2012001196A/es not_active Application Discontinuation
- 2010-07-28 MX MX2015002869A patent/MX348197B/es unknown
- 2010-07-28 US US12/844,920 patent/US20110039826A1/en not_active Abandoned
- 2010-07-28 AU AU2010276741A patent/AU2010276741B2/en active Active
- 2010-07-28 UA UAA201202214A patent/UA110463C2/ru unknown
- 2010-07-28 WO PCT/US2010/002109 patent/WO2011014248A1/en not_active Ceased
- 2010-07-28 EP EP10739413.2A patent/EP2459173B1/en active Active
- 2010-07-28 IN IN1237DEN2012 patent/IN2012DN01237A/en unknown
- 2010-07-28 EA EA201270205A patent/EA025277B1/ru unknown
- 2010-07-28 KR KR1020127004651A patent/KR101762285B1/ko active Active
- 2010-07-28 GE GEAP201012599A patent/GEP201606513B/en unknown
- 2010-07-28 CA CA2769531A patent/CA2769531C/en active Active
- 2010-07-28 CN CN2010800415230A patent/CN102548539A/zh active Pending
- 2010-07-28 JP JP2012522810A patent/JP2013500965A/ja active Pending
- 2010-07-28 NZ NZ59809610A patent/NZ598096A/en unknown
- 2010-07-28 SG SG10201404483VA patent/SG10201404483VA/en unknown
- 2010-07-28 PE PE2012000132A patent/PE20120788A1/es not_active Application Discontinuation
- 2010-07-28 MY MYPI2012000438A patent/MY174084A/en unknown
- 2010-07-28 SG SG2012005401A patent/SG177751A1/en unknown
- 2010-07-28 CN CN201410112836.0A patent/CN103893186B/zh active Active
- 2010-07-30 AR ARP100102812 patent/AR077436A1/es not_active Application Discontinuation
- 2010-07-30 TW TW099125531A patent/TWI522357B/zh active
- 2010-08-02 UY UY32822A patent/UY32822A/es not_active Application Discontinuation
-
2012
- 2012-01-27 TN TNP2012000046A patent/TN2012000046A1/en unknown
- 2012-01-30 IL IL217839A patent/IL217839A/en active IP Right Grant
- 2012-01-31 CL CL2012000261A patent/CL2012000261A1/es unknown
- 2012-02-08 ZA ZA2012/00944A patent/ZA201200944B/en unknown
- 2012-02-09 CO CO12022583A patent/CO6612185A2/es not_active Application Discontinuation
- 2012-02-16 MA MA34640A patent/MA33533B1/fr unknown
- 2012-02-17 CR CR20120084A patent/CR20120084A/es unknown
- 2012-02-29 EC ECSP12011703 patent/ECSP12011703A/es unknown
-
2013
- 2013-06-11 US US13/914,705 patent/US9127011B2/en active Active
-
2015
- 2015-02-05 JP JP2015021023A patent/JP6014695B2/ja active Active
- 2015-08-28 US US14/838,878 patent/US9504693B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20201681T1 (hr) | Inhibitor aurora a kinaze | |
| RU2015149527A (ru) | Производные доластатина 10 и ауристатинов | |
| AR077436A1 (es) | Composiciones farmaceuticas para el tratamiento del cancer y otras enfermedades o trastornos que contienen el 4-{[9-cloro-7-(2-fluoro-6-metoxifenil)-5h-pirimido-[5,4-d][2]benzacepin-2-il]amino}-2-metoxibenzoico, o una de sus sales farmaceuticamente aceptables. | |
| JP2016515561A5 (enExample) | ||
| JP2017533930A5 (enExample) | ||
| BR112015023705A2 (pt) | composto da fórmula (ia) ou um sal, hidrato, solvato ou forma cristalina farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto, composto e método para síntese do composto da fórmula (ia) | |
| JP2019524883A5 (enExample) | ||
| JP2017517565A5 (enExample) | ||
| JP2014508804A5 (enExample) | ||
| HRP20210183T1 (hr) | 18f-obilježeni inhibitori specifičnog membranskog antigena prostate (psma) i njihova uporaba kao sredstava za vizualizaciju raka prostate | |
| JP2017507175A5 (enExample) | ||
| JP2020097577A5 (enExample) | ||
| JP2015512413A5 (enExample) | ||
| JP2019535723A5 (enExample) | ||
| JP2015098469A5 (enExample) | ||
| JP2016528273A5 (enExample) | ||
| JP2019534265A5 (ja) | 医薬組成物およびその投与方法 | |
| EA201691136A1 (ru) | Производное на основе 1,2-нафтохинона и способ его получения | |
| HRP20220683T1 (hr) | Liječenje parkinsonove bolesti | |
| EA201691342A1 (ru) | Пиразолоновые соединения и их применение | |
| RU2018101431A (ru) | Ингибиторы индоламин-2,3-диоксигеназы | |
| JP2017505785A5 (enExample) | ||
| RU2016138577A (ru) | Жидкая фармцевтическая композиция | |
| EA201690230A1 (ru) | Соединения триазолона и их применения | |
| JP2019519512A5 (enExample) |